Compare Gitlab Inc (GTLB) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Medtronic PLC — how do they compare? Gitlab Inc trades at $55.09 (market cap $8.92B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 12.6× Gitlab Inc's market cap, and Medtronic PLC pays a 3.28% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Medtronic PLC for 63 Days on average.
| GTLB | MDT | |
|---|---|---|
Market Cap | $8.92B | $112.24B |
Volume | 4,716,893 | 105,663,236 |
Sector | Technology | Health |
52-Week High | $55.09 | $105.35 |
52-Week Low | $19.42 | $73.75 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $7.66B | $131.58B |
Dividend Yield | — | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $53.56, up 3.02% with strong technical momentum as it approaches resistance at $54. The stock shows bullish moving average signals despite an overbought RSI. Fundamentally, revenue growth remains robust at 21.3% in Q2 2026 with consistent earnings beats, though profitability metrics like negative net income margin and ROE highlight ongoing challenges. Recent news highlights AI-driven product traction and raised guidance, fueling investor optimism.
Outlook: GitLab's AI integration and sales momentum support upside potential, but high valuation multiples and persistent cash burn pose risks. Analyst consensus is mixed with a $49.71 price target below current levels, suggesting cautious optimism amid execution and competitive pressures.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
